论文部分内容阅读
为了解泛拉西洛韦(500mg,2/d)抑制HIV感染者生殖器单纯疱疹复发的疗效和安全性,研究者设计了一项随机、双盲、安慰剂对照、多中心试验。总计293名接受了抗逆转录病毒治疗的HIV血清阳性者入选,其中25％ CD4~+细胞数<200/μl,43％血浆HIV RNA水平≥400 copies/ml,38％按CDC分级标准为HIV Ⅲ级。该293名感染者被随机分为2组,安慰剂组99名,泛拉西洛韦组194名。结果显示接受泛拉西洛韦治疗组6个月未发生生殖器疱疹复发者百分比为65％,而安慰剂组为26％;与泛拉西洛韦治疗组相比,安慰剂组首次生殖器疱疹复发时间明显较早,平均59d,而泛拉西洛韦组平均>180d;同时泛拉西洛韦耐受性好,在接受
Researchers designed a randomized, double-blind, placebo-controlled, multicentre trial to determine the efficacy and safety of panaxxolol (500 mg, 2 / d) in suppressing the recurrence of genital herpes in HIV-infected patients. A total of 293 HIV seropositive patients were enrolled in antiretroviral therapy, with 25% CD4 + cells <200 / μl, 43% plasma HIV RNA levels ≥ 400 copies / ml and 38% HIV-positive Ⅲ level. The 293 patients were randomly divided into two groups: 99 in the placebo group and 194 in the panrasilovir group. The results showed that the percentage of patients who received genisilazepir received 6 months without genital herpes relapse was 65%, compared with 26% in the placebo group, and the placebo group had the first recurrence of genital herpes compared with the panrasiclovir-treated group The time was significantly earlier, with an average of 59d, while the panrasiclovir group averaged> 180d; at the same time, panaxxolv was well tolerated,